

**2023 Insurer Reporting  
Most Prescribed Drugs**

Drug	Class	Prescriptions
<b>Influenza virus vaccine</b> <i>Includes brand names: Afluria, Fluarix, Flulaval, and Fluzone</i>	Vaccines	221,220
<b>Levothyroxine sodium</b> <i>Includes brand names: Euthyrox, Levoxyl, Synthroid, and Tirosint</i>	Thyroid agents	169,336
<b>Atorvastatin calcium</b> <i>Includes brand names: Atorvaliq and Lipitor</i>	Antihyperlipidemics	166,505
<b>Lisinopril</b> <i>Includes brand names: Prinivil, Qbrelis, and Zestril</i>	Antihypertensives	161,174
<b>Amphetamine-dextroamphetamine</b> <i>Includes brand names: Adderall and Mydaysis</i>	ADHD/anti-narcolepsy/anti-obesity/ anorexiant	156,001
<b>Albuterol Sulfate</b> <i>Includes brand names: ProAir, Proventil, and Ventolin</i>	Anti-asthmatic/bronchodilator agents	141,372
<b>Metformin HCl</b>	Antidiabetics	137,692
<b>Bupropion HCl</b>	Antidepressants	126,612
<b>COVID-19 (SARS-CoV-2) mRNA virus vaccine</b> <i>Moderna and Pfizer-BioNTech</i>	Vaccines	124,948
<b>Sertraline HCl</b> <i>Includes brand name: Zoloft</i>	Antidepressants	119,432

2023 insurer report information

<https://dfr.oregon.gov/drugtransparency/Documents/20231207-dpt-hearing/Prescription-Drug-Price-Transparency-Annual-Report-2023.pdf#page=50>

**2023 Insurer Reporting  
Most Costly Drugs**

<b>Drug</b>	<b>Class</b>	<b>Total Spent</b>
<b>Adalimumab</b> <i>Brand name: Humira</i>	Analgesics/anti-inflammatory	\$75,241,110
<b>Ustekinumab</b> <i>Brand name: Stelara</i>	Dermatologicals	\$28,957,943
<b>Pembrolizumab</b> <i>Brand name: Keytruda</i>	Antineoplastics and adjunctive therapies	\$28,248,898
<b>Bictegravir-Emtricitabine-Tenofovir Alafenamide Fumarate</b> <i>Brand name: Biktarvy</i>	Antivirals	\$26,988,465
<b>Etanercept</b> <i>Brand name: Enbrel</i>	Analgesics/anti-inflammatory	\$22,017,823
<b>Eluxacaftor-Tezacaftor-Ivacaftor</b> <i>Brand name: Trikafta</i>	Respiratory agents	\$21,559,651
<b>Secukinumab</b> <i>Brand name: Cosentyx</i>	Dermatologicals	\$18,723,855
<b>Vedolizumab</b> <i>Brand name: Entyvio</i>	Gastrointestinal agent	\$17,655,131
<b>Infliximab-dyyb</b> <i>Brand name: Inflectra</i>	Gastrointestinal agent	\$16,516,923
<b>Risankizumab-rzaa</b> <i>Brand name: Skyrizi</i>	Dermatologicals	\$15,517,811

2023 insurer report information

<https://dfr.oregon.gov/drugtransparency/Documents/20231207-dpt-hearing/Prescription-Drug-Price-Transparency-Annual-Report-2023.pdf#page=50>

**2023 Insurer Reporting**  
**Drugs with greatest increase in plan spending**

Drug	Class	Year-Over-Year Increase
<b>Pembrolizumab</b> <i>Brand name: Keytruda</i>	Antineoplastics and adjunctive therapies	\$11,840,653
<b>Risankizumab-rzaa</b> <i>Brand name: Skyrizi</i>	Dermatologicals	\$8,385,287
<b>Infliximab-dyyb</b> <i>Brand name: Inflectra</i>	Gastrointestinal agents	\$5,489,239
<b>Elexacaftor-Tezacaftor-Ivacaftor</b> <i>Brand name: Trikafta</i>	Respiratory agents	\$4,417,699
<b>Immune Globulin (Human) IV</b> <i>Brand name: Gammagard</i>	Passive immunizing and treatment agents	\$4,312,556
<b>Adalimumab</b> <i>Brand name: Humira</i>	Analgesics/anti-inflammatory	\$3,682,844
<b>Dupilumab</b> <i>Brand name: Dupixent</i>	Dermatologicals	\$3,333,668
<b>Semaglutide</b> <i>Brand name: Rybelsus/Ozempic</i>	Antidiabetics	\$3,238,534
<b>Ustekinumab</b> <i>Brand name: Stelara</i>	Dermatologicals	\$3,077,394
<b>Brentuximab Vedotin</b> <i>Brand name: Adcetris</i>	Antineoplastics and adjunctive therapies	\$3,020,976

2023 insurer report information

<https://dfr.oregon.gov/drugtransparency/Documents/20231207-dpt-hearing/Prescription-Drug-Price-Transparency-Annual-Report-2023.pdf#page=50>